Infleqtion (CCCX) director Johnson granted options and common shares

Rhea-AI Filing Summary

Infleqtion, Inc. director Kristina M. Johnson reported equity awards linked to the merger of Churchill Capital Corp X with ColdQuanta. She was granted 373,458 stock options at an exercise price of $0.00 per share, which vest monthly from June 1, 2024 in 36 equal installments, contingent on continued service.

Johnson also reported an acquisition of 33,120 shares of common stock for $0.00 per share. These shares are held indirectly by Catalyzer Ventures, LP Fund I, over which she has voting and investment power and may therefore be deemed a beneficial owner.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider JOHNSON KRISTINA M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	373,458	$0.00	--
Grant/Award	Common Stock	33,120	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 373,458 shares (Direct); Common Stock — 33,120 shares (Indirect, See footnote)

Footnotes (1)

1. Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 8, 2025, by and among Churchill Capital Corp X, a Delaware corporation now known as Infleqtion, Inc. ("Acquiror"), AH Merger Sub I, Inc., a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub I"), AH Merger Sub II, LLC, a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub II" and together with Merger Sub I, "Merger Subs") and ColdQuanta, Inc. (the "Company") pursuant to which (a) Merger Sub I was merged with and into the Company, and the Company continued as the surviving corporation and immediately thereafter, (b) the Company merged with and into Merger Sub II, and Merger Sub II became the surviving company and continued in existence as a wholly-owned subsidiary of Acquiror (collectively, the "Mergers"). In connection with the Mergers, Acquiror changed its name to Infleqtion, Inc. (the "Issuer"). Represents shares of common stock of the Issuer issued upon conversion of the Company's Series C-1 preferred stock pursuant to the Mergers. Held directly by Catalyzer Ventures, LP Fund I ("Catalyzer"). Dr. Johnson may be deemed to beneficially own shares held by Catalyzer by virtue of her voting power and investment power over such shares. The shares vest on a monthly basis beginning on June 1, 2024 with respect to 1/36 of the total number of shares until such time as the option is 100% vested, subject to the continuous service of the Reporting Person as of each such date. Pursuant to the Mergers, the legacy stock options of the Company were automatically converted into the right to receive stock options of the Issuer with the same terms and conditions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON KRISTINA M

(Last) (First) (Middle)

C/O INFLEQTION, INC.

1315 WEST CENTURY DRIVE, SUITE 150

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Churchill Capital Corp X/Cayman [ INFQ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A(1)		33,120(2)	A	(1)	33,120	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9	02/13/2026		A(1)		373,458		(4)	06/05/2034	Common Stock	373,458	(5)	373,458	D

Explanation of Responses:

1. Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 8, 2025, by and among Churchill Capital Corp X, a Delaware corporation now known as Infleqtion, Inc. ("Acquiror"), AH Merger Sub I, Inc., a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub I"), AH Merger Sub II, LLC, a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub II" and together with Merger Sub I, "Merger Subs") and ColdQuanta, Inc. (the "Company") pursuant to which (a) Merger Sub I was merged with and into the Company, and the Company continued as the surviving corporation and immediately thereafter, (b) the Company merged with and into Merger Sub II, and Merger Sub II became the surviving company and continued in existence as a wholly-owned subsidiary of Acquiror (collectively, the "Mergers"). In connection with the Mergers, Acquiror changed its name to Infleqtion, Inc. (the "Issuer").

2. Represents shares of common stock of the Issuer issued upon conversion of the Company's Series C-1 preferred stock pursuant to the Mergers.

3. Held directly by Catalyzer Ventures, LP Fund I ("Catalyzer"). Dr. Johnson may be deemed to beneficially own shares held by Catalyzer by virtue of her voting power and investment power over such shares.

4. The shares vest on a monthly basis beginning on June 1, 2024 with respect to 1/36 of the total number of shares until such time as the option is 100% vested, subject to the continuous service of the Reporting Person as of each such date.

5. Pursuant to the Mergers, the legacy stock options of the Company were automatically converted into the right to receive stock options of the Issuer with the same terms and conditions.

	/s/ Jason D. Hall, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Infleqtion (CCCX) report for Kristina M. Johnson?

Kristina M. Johnson reported receiving 373,458 stock options and 33,120 shares of Infleqtion common stock at an exercise or acquisition price of $0.00 per share, reflecting merger-related equity awards and conversions tied to the Churchill Capital Corp X and ColdQuanta combination.

How do Kristina M. Johnson’s Infleqtion (CCCX) stock options vest?

Johnson’s Infleqtion stock options vest monthly over three years. Beginning June 1, 2024, 1/36 of the 373,458 options vest each month, so long as she continues to provide service on each vesting date, until the option is fully vested.

Why did Kristina M. Johnson receive Infleqtion (CCCX) equity in this Form 4?

Her equity stems from a merger where Churchill Capital Corp X, now Infleqtion, combined with ColdQuanta. Legacy ColdQuanta stock options converted into Infleqtion options on the same terms, and preferred stock converted into Infleqtion common shares, resulting in the reported grants and share issuances.

Who actually holds the 33,120 Infleqtion (CCCX) shares reported for Kristina M. Johnson?

The 33,120 common shares are held by Catalyzer Ventures, LP Fund I. Johnson may be deemed to beneficially own these shares because she has voting and investment power over Catalyzer’s holdings, even though the ownership is reported as indirect in the Form 4.

What is the relationship between Churchill Capital Corp X, Infleqtion (CCCX), and ColdQuanta?

Churchill Capital Corp X completed a merger with ColdQuanta through two merger subsidiaries. After these transactions, the surviving entity became a wholly owned subsidiary, and Churchill Capital Corp X changed its name to Infleqtion, Inc., the issuer of the reported options and shares.